Improvement of an encapsulation process for the preparation of pro- and prebiotics-loaded bioadhesive microparticles by using experimental design

Pliszczak, D.; Bourgeois, Sandrine; Bordes, Claire; Valour, Jean‐Pierre; Mazoyer, Marie-Andrée; Orecchioni, A. M.; Nakache, E.; Lantéri, Pierre

doi:10.1016/j.ejps.2011.06.011

Cited by 44 publications

(24 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Freeze-drying and encapsulation are methods widely applied to preserve and protect microbial viability (Pliszczak et al, 2011;Muller et al, 2013). Encapsulation protects the active ingredients against stressing physical-chemical factors such as heat, humidity, extreme pH, harmful substances, etc.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation and subsequent freeze-drying of Lactobacillus reuteri CRL 1324 for its potential inclusion in vaginal probiotic formulations

Tomás

Gregorio

Terraf

et al. 2015

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Probiotic formulations must include a high number of viable and active microorganisms. In this work, the survival of human vaginal Lactobacillus reuteri CRL 1324 during encapsulation, lyophilization and storage, and the activity of encapsulated and/or freeze-dried bacterial cells were evaluated. Extrusion-ionic gelation technique was applied to encapsulate L. reuteri CRL 1324, using xanthan and gellan. Encapsulated and free bacterial cells were freeze-dried with or without lactose and skim milk as lyoprotectors. The different systems obtained were stored at room temperature and at 4°C for 150days. The following determinations were performed: L. reuteri CRL 1324 viability, microorganism released from capsules, survival in a medium simulating the vaginal fluid and maintenance of beneficial properties (growth inhibition of opportunistic pathogenic Streptococcus agalactiae NH 17 and biofilm formation). L. reuteri CRL 1324 encapsulation was efficient, allowing the recovery of a high number of entrapped lactobacilli. The survival of encapsulated L. reuteri during lyophilization and storage was significantly higher in the presence of lyoprotectors. At the end of storage, the highest numbers of viable cells were obtained in free or encapsulated cells freeze-dried with lyoprotectors, stored at 4°C. Encapsulated and/or lyophilized L. reuteri cells maintained their viability in simulated vaginal fluid as well as the ability to inhibit S. agalactiae NH 17 growth and to form biofilm. Encapsulated and freeze-dried L. reuteri CRL 1324 can be included in a suitable pharmaceutical form for vaginal application to prevent or treat urogenital infections in women.

show abstract

Section: Introductionmentioning

confidence: 99%

Encapsulation and subsequent freeze-drying of Lactobacillus reuteri CRL 1324 for its potential inclusion in vaginal probiotic formulations

Tomás

Gregorio

Terraf

et al. 2015

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…For this purpose, calcium pectinate was deeply studied as a drug carrier for colon-specific delivery because this complex can reduce the solubility of pectin and keep stable in low pH environment [128]. Besides, pectin has been combined with other polymers, including 4-aminothiophenol [131], chitosan [132], hyaluronic acid [133] or poly (lactide-co-glycolide) [134], showing good results as controlled drug release devices.…”

Section: Pectinmentioning

confidence: 99%

Novel nanoparticle materials for drug/food delivery-polysaccharides

Chen

Liu

Wong

2016

Physical Sciences Reviews

View full text Add to dashboard Cite

“…The combination of pectin and a second polymer into a composite may alter degree of swelling and change mechanical properties (Liu et al, 2003), improving in the most cases the stability of the drug and controlling the drug release. As a case in point, pectin has been combined with 4-aminothiophenol (Perera et al, 2010), chitosan (Fernandez-Hervas & Fell, 1998), hyaluronic acid (Pliszczak et al, 2011) or poly (lactide-co-glycolide) (Liu et al, 2004), showing good results as controlled drug release devices.…”

Section: Pectinmentioning

confidence: 99%